Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer

20093,837 citationsJournal Articlebronze Open Access

Authors

Eric Van Cutsem · Universitair Ziekenhuis Leuven

Claus-Henning Köhne · Klinikum Oldenburg

Erika Hitre

J. Załuski · Greater Poland Cancer Center

Chung-Rong Chang Chien · Taoyuan Chang Gung Memorial Hospital

Anatoly Makhson · Moscow City Oncology Hospital №62

Geert D’Haens · Imelda Hospital

Abstract

First-line treatment with cetuximab plus FOLFIRI, as compared with FOLFIRI alone, reduced the risk of progression of metastatic colorectal cancer. The benefit of cetuximab was limited to patients with KRAS wild-type tumors. (ClinicalTrials.gov number, NCT00154102.)

Topics & Keywords

Colorectal Cancer Treatments and Studies Genetic factors in colorectal cancer Lung Cancer Treatments and Mutations

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 360, Issue 14, pp. 1408-1417

DOI: 10.1056/nejmoa0805019

Field-Weighted Citation Impact: 160.55